摘要
The incidence of intractable age-related neurodegenerative conditions such as Alzheimer＇s and Parkinson＇s diseases and age-related macular degeneration is projected to increase substantially over the coming decades with the ageing of the global population. While the burden of disease associ- ated with other chronic conditions has decreased in recent times due to improved diagnosis and treatment, current therapies for neurodegenerative diseases still fall short in that they are only effective in treating signs and symptoms - they do little to slow or prevent disease progress. Thus, there is an urgent need for treatments that address disease progression.
The incidence of intractable age-related neurodegenerative conditions such as Alzheimer＇s and Parkinson＇s diseases and age-related macular degeneration is projected to increase substantially over the coming decades with the ageing of the global population. While the burden of disease associ- ated with other chronic conditions has decreased in recent times due to improved diagnosis and treatment, current therapies for neurodegenerative diseases still fall short in that they are only effective in treating signs and symptoms - they do little to slow or prevent disease progress. Thus, there is an urgent need for treatments that address disease progression.
基金
supported by Sydney Medical School,Brain Foundation,Tenix Corporation and Sir Zelman Cowen Universities Fund
supported by a National Health and Medical Research Council of Australia(NHMRC)Early Career Fellowship
